grant

Early interventions at ART initiation to reduce the HIV-1 reservoir and enhance adaptive immune responses

Organization UNIVERSITY OF PENNSYLVANIALocation PHILADELPHIA, UNITED STATESPosted 19 Aug 2024Deadline 31 Jul 2029
NIHUS FederalResearch GrantFY2025AIDS VirusAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAddressAffectAnti-viral TherapyAntibody TherapyAntigenic DeterminantsB-Cell Chronic Lymphocytic Leukemia Associated OncogeneB-cell Leukemia 1BCLBCL1 OncogeneBinding DeterminantsBlood PlasmaCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCell BodyCell FunctionCell PhysiologyCell ProcessCell Surface ProteinsCell SurvivalCell ViabilityCellsCellular FunctionCellular PhysiologyCellular ProcessClinical TreatmentClinical TrialsDevelopmentDisease remissionEarly InterventionEngraftmentEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEpitopesExpression SignatureFrequenciesFutureGene Expression ProfileGoalsHIVHIV InfectionsHIV-1HIV-IHIV1HTLV-III InfectionsHTLV-III-LAV InfectionsHeterograftHeterologous TransplantationHumanHuman Immunodeficiency Virus Type 1Human Immunodeficiency VirusesHuman T-Lymphotropic Virus Type III InfectionsHuman immunodeficiency virus 1IFN-GammaIFN-gIFN-γIFNGIFNγImmuneImmune InterferonImmune mediated therapyImmune responseImmunesImmunityImmunochemical ImmunologicImmunologicImmunologicalImmunologicallyImmunologically Directed TherapyImmunologicsImmunotherapyIndividualInfectionInfusionInfusion proceduresInterferon GammaInterferon Type IIInterruptionInterventionLAV-HTLV-IIILymphadenopathy-Associated VirusMeasuresMediatingModern ManNIAIDNational Institute of Allergy and Infectious DiseaseOutcomeParticipantPersonsPhasePhenotypePlasmaPlasma SerumPolandPropertyRemissionReportingResistanceReticuloendothelial System, Serum, PlasmaSamplingSubcellular ProcessSystemT cell responseT-CellsT-LymphocyteT4 CellsT4 LymphocytesT8 CellsT8 LymphocytesTeff cellTherapeuticTimeUniversitiesValidationViralViral reservoirVirusVirus reservoirVirus-HIVXenograftXenograft procedureXenotransplantationadaptive immune responseantagonismantagonistantibody based therapiesantibody treatmentantibody-based therapeuticsantibody-based treatmentantiretroviral therapyantiretroviral treatmentclinical interventionclinical therapydevelopmentaleffector T cellepigeneticallyfeature selectiongene expression patterngene expression signaturehost responsehumanized micehumanized mouseimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunoresponseimprintimprovedin vivoinfusionslFN-Gammamouse modelmurine modelneutralizing antibodynovelpreservationresistantresponsesuccessthymus derived lymphocytetranscriptional profiletranscriptional signaturetranscriptomicstrial regimentrial treatmentvalidationsviral infectious disease treatmentxeno-transplantxeno-transplantation
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

Increasing efforts are being made to understand whether early intervention after HIV-1 infection can enable long-
term viral control and reduction of the viral reservoir through the preservation of HIV-1-specific immune

responses. Recently, the pioneering eCLEAR phase 1b/2a clinical trial led by MPI SØgaard, found that

administration of the…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
Early interventions at ART initiation to reduce the HIV-1 reservoir and enhance adaptive immune responses — UNIVERSITY O | Dev Procure